0000000000794657

AUTHOR

Cristina Rodríguez

showing 8 related works from this author

Data from an international multi-centre Study of Statistics and Mathematics Anxieties and Related Variables in University Students (the SMARVUS Datas…

2023

This large, international dataset contains survey responses from N = 12,570 students from 100 universities in 35 countries, collected in 21 languages. We measured anxieties (statistics, mathematics, test, trait, social interaction, performance, creativity, intolerance of uncertainty, and fear of negative evaluation), self-efficacy, persistence, and the cognitive reflection test, and collected demographics, previous mathematics grades, self-reported and official statistics grades, and statistics module details. Data reuse potential is broad, including testing links between anxieties and statistics/mathematics education factors, and examining instruments’ psychometric properties across differ…

educationminäpystyvyysStatistics; mathematics; anxiety education; jangle fallacy;Polymers and Plasticsjangle fallacymatematiikkaopiskelijatoppiminenmathematicsStatisticsSettore M-PSI/03 - Psicometriaanxietykansainvälinen vertailupsykometriikkastatisticstilastotiedekorkeakouluopiskeluahdistustutkimusaineistoGeneral Environmental Science
researchProduct

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct

Autoimmune hepatitis triggered by COVID-19

2021

We present the case of a 60-year-old woman with no drug allergies or toxic habits, with hypothyroidism and receiving treatment with levothyroxine.

Drugendocrine system2019-20 coronavirus outbreakAllergyendocrine system diseasesCoronavirus disease 2019 (COVID-19)business.industrymedia_common.quotation_subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GastroenterologyMEDLINELevothyroxineGeneral MedicineAutoimmune hepatitismedicine.diseaseImmunologymedicinebusinesshormones hormone substitutes and hormone antagonistsmedia_commonmedicine.drugRevista Española de Enfermedades Digestivas
researchProduct

Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.

2021

Abstract Aim To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] in real life. Methods Patients from the prospectively maintained ENEIDA registry and treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, and 16. Results A total of 113 patients were included. They were exposed to tofacitinib for a median time of 44 weeks. Response and remission at Week 8 were 60% and 31%, respectively. In multivariate analysis, higher PMS at Week 4 (odds ratio [OR] = 0].2; 95% confidence interval [CI] = 0].1–0.4) was the only variable …

Malemedicine.medical_specialtyPiperidinesRecurrenceInternal medicinemedicineHumansRegistriesAdverse effectProtein Kinase Inhibitorsulcerative colitisTofacitinibDose-Response Relationship Drugbusiness.industryTtofacitinib ulcerative colitisRemission InductionHazard ratioPatient AcuityGastroenterologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUlcerative colitisConfidence intervaldigestive system diseasesDiscontinuationPyrimidinesTreatment OutcomeSpainCohortColitis UlcerativeFemaleDrug MonitoringbusinessTtofacitinib
researchProduct

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

2021

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and…

Crohn’s diseasemedicine.medical_specialtyPopulationDiseaseInflammatory bowel diseasedigestive systemArticle03 medical and health sciences0302 clinical medicineInterquartile rangeinflammatory bowel diseaseInternal medicineEpidemiologyMedicineeducationCrohn’s disease epidemiology incidence inflammatory bowel disease ulcerative colitisulcerative colitisCrohn's diseaseeducation.field_of_studybusiness.industryIncidence (epidemiology)RGeneral Medicinemedicine.diseaseUlcerative colitisdigestive system diseasesCrohn's disease030220 oncology & carcinogenesisincidenceMedicine030211 gastroenterology & hepatologyepidemiologybusiness
researchProduct

Botulinum Toxin Injection Plus Topical Diltiazem for Chronic Anal Fissure: A Randomized Double-Blind Clinical Trial and Long-term Outcome.

2021

BACKGROUND: Chemical sphincterotomy avoids the risk of permanent incontinence in the treatment of chronic anal fissure, but it does not reach the efficacy of surgery and recurrence is high. Drug combination has been proposed to overcome these drawbacks.; OBJECTIVE: This study aimed to compare the clinical, morphological, and functional effects of combined therapy with botulinum toxin injection and topical diltiazem in chronic anal fissure and to assess the long-term outcome after healing.; DESIGN: This is a randomized, controlled, double-blind, 2-arm, parallel-group trial with a long-term follow-up.; SETTINGS: This study was conducted at a tertiary care center.; PATIENTS: A total of 70 cons…

Gynecologymedicine.medical_specialtybusiness.industryGastroenterologyChronic anal fissureBotulinum toxin injectionGeneral MedicineTopical diltiazemPlaceboSymptomatic reliefClinical trialDouble blindFissure recurrenceBotulinum toxinmedicineCombined therapyDiltiazembusinessChronic anal fissuremedicine.drug
researchProduct

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicen…

2019

Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. Methods PSC-IBD patients were identified from the Spanish ENEIDA registry of GETECCU. Additional data were collected using the AEG-REDCap electronic data capture tool. Results In total, 277 PSC-IBD patients were included, with an incidence rate of 61 PSC cases per 100 000 IBD patient-years, 69.7% …

AdultMalemedicine.medical_specialtyendocrine system diseasesColorectal cancerCholangitis SclerosingRisk AssessmentGastroenterologyInflammatory bowel diseasedigestive systemPrimary sclerosing cholangitisCholangiocarcinomaBile Ducts ExtrahepaticRisk FactorsInterquartile rangeinflammatory bowel diseaseInternal medicineHumansMedicineRetrospective Studiesbusiness.industryPrimary sclerosing cholangitisHazard ratiodigestive oral and skin physiologyGastroenterologyRetrospective cohort studyGeneral MedicineOdds ratioMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurvival AnalysisUlcerative colitisdigestive system diseasesPatient Care ManagementBile Ducts IntrahepaticSpainFemalePrimary sclerosing cholangitis inflammatory bowel disease malignancyColorectal Neoplasmsbusinessmalignancy
researchProduct

Deficient p27 Phosphorylation at Serine 10 Increases Macrophage Foam Cell Formation and Aggravates Atherosclerosis Through a Proliferation-Independen…

2011

OBJECTIVE: Genetic ablation of the growth suppressor p27(Kip1) (p27) in the mouse aggravates atherosclerosis coinciding with enhanced arterial cell proliferation. However, it is unknown whether molecular mechanisms that limit p27's protective function contribute to atherosclerosis development and whether p27 exerts proliferation-independent activities in the arterial wall. This study aims to provide insight into both questions by investigating the role in atherosclerosis of p27 phosphorylation at serine 10 (p27-phospho-Ser10), a major posttranslational modification of this protein. METHODS AND RESULTS: Immunoblotting studies revealed a marked reduction in p27-phospho-Ser10 in atheroscleroti…

Malerho GTP-Binding ProteinsRHOAMoesinMiceApolipoproteins ERadixinSerinemedicineAnimalsHumansProtein phosphorylationPhosphorylationProtein kinase ACell ProliferationFoam cellMice Knockoutrho-Associated KinasesbiologyArteriesAtherosclerosismedicine.diseaseCell biologyMice Inbred C57BLDisease Models AnimalAtheromaCase-Control StudiesImmunologyDisease Progressionbiology.proteinPhosphorylationFemalerhoA GTP-Binding ProteinCardiology and Cardiovascular MedicineCyclin-Dependent Kinase Inhibitor p27Foam CellsSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct